BioCentury | Apr 14, 2016
Distillery Therapeutics

Therapeutics: Artemin (ARTN); glial cell line-derived neurotrophic factor family receptor α 3 (GFRα3)

...Neurology INDICATION: Pain Mouse studies suggest inhibiting GFRα3 or its ligand ARTN could help treat cold...
...pain. In mouse models of inflammatory and neuropathic pain, intradermal injection of an antibody against ARTN...
...could include testing inhibitors of GFRα3 or ARTN in additional models of cold allodynia. TARGET/MARKER/PATHWAY: Artemin (ARTN)...
BioCentury | Jul 13, 2015
Finance

Big news

...MS (RRMS). Biogen also plans to have data from a Phase II trial of Neublastin artemin/enovin...
...Tysabri natalizumab Secondary progressive multiple sclerosis (SPMS) Ph IIIb data 2H15 Biogen Inc. (NASDAQ:BIIB) Neublastin artemin/enovin...
BioCentury | Jun 18, 2012
Clinical News

Neublastin artemin/enovin: Interim Phase I data

...16, 2010). Biogen Idec Inc. (NASDAQ:BIIB), Weston, Mass. NsGene A/S , Ballerup, Denmark Product: Neublastin artemin/enovin...
BioCentury | Jun 18, 2012
Clinical News

Neublastin artemin/enovin: Phase I data

...16, 2010). Biogen Idec Inc. (NASDAQ:BIIB), Weston, Mass. NsGene A/S , Ballerup, Denmark Product: Neublastin artemin/enovin...
BioCentury | Aug 16, 2010
Company News

Biogen Idec, NsGene deal

...The partners granted Biogen Idec exclusive, worldwide rights to develop and commercialize Neublastin artemin/enovin for all...
BioCentury | Sep 7, 2009
Clinical News

Neublastin artemin/enovin: Phase I started

...11, 2000). Biogen Idec Inc. (NASDAQ:BIIB), Cambridge, Mass. NsGene A/S , Ballerup, Denmark Product: Neublastin artemin/enovin...
BioCentury | Mar 31, 2008
Clinical News

Biogen Idec, NsGene preclinical data

...Data from rats with dorsal root crush showed that Neublastin artemin promoted the regeneration of damaged...
...11, 2000). Biogen Idec Inc. (NASDAQ:BIIB), Cambridge, Mass. NsGene A/S , Ballerup, Denmark Product: Neublastin artemin/enovin...
BioCentury | Jul 12, 2004
Product Development

Neurotrophic factor frustration

...by the first quarter of 2005. Biogen Idec Inc. (BIIB, Cambridge, Mass.) is developing Neublastin artemin...
BioCentury | Oct 13, 2003
Clinical News

Biogen preclinical data

...Researchers published in Nature Medicine that artemin produced dose- and time-related reversal of nerve injury-induced pain...
...Neublastin is in Phase I trials. Biogen Inc. (BGEN), Cambridge, Mass., et al. Product: Neublastin (artemin/enovin...
Items per page:
1 - 9 of 9